Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2/Phase 3
COBRA
Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery
- NCT04068103 ↗
- Active, not recruiting
- NRG Oncology
- Focused
We haven't built an HCP commentary report on COBRA yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on COBRA so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 4 |
The trial
ClinicalTrials.gov- Official title
- Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients With Stage IIA Colon Cancer (COBRA)
- Phase
- Phase 2/Phase 3
- Status
- Active, not recruiting
- Conditions
- Colon Adenocarcinoma; Stage IIA Colon Cancer AJCC v8
- Interventions
- Capecitabine; Fluorouracil; Leucovorin; Leucovorin Calcium; Oxaliplatin; Patient Observation
- Arms
- Arm I (blood stored and tested for ctDNA later) · Active comparator
- Arm II (blood tested for ctDNA at baseline) · Experimental
- Enrollment
- 635
- Primary outcomes
- Clearance of Circulating Tumor Deoxyribonucleic Acid (ctDNA) (to Undetectable Levels) for the "Baseline ctDNA Detected" Patient Subset (Phase II)
- Recurrence-free Survival (RFS) the "Baseline ctDNA Detected" Patient Subset (Phase III)
- Sponsor
- NRG Oncology with National Cancer Institute (NCI)
- Start
- Dec 16, 2019
- Primary completion
- Jun 30, 2023
- Results posted
- Yes
- Registry record
- NCT04068103 · updated May 7, 2025